An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
Recruiting now · Phase 2
Conditions studied: Gastroesophageal Junction (GEJ) Adenocarcinoma
In brief
This study is to evaluate the effectiveness of treatment for esophagogastric junction carcinoma, total neoadjuvant therapy (TNT) including pembrolizumab and FLOT is conducted, aiming to choose between surgery or organ preservation treatment strategies.
Key facts
- Study ID
- NCT07018570
- Run by
- National Cancer Center Hospital East
- People needed
- 26
- Starts
- 2025-07-24
- Expected to finish
- 2031-06-01
- Last updated by the study team
- 2025-08-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- National Cancer Center Hospital East — Kashiwa, Chiba, Japan (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.